Contact ABPI

Association of the British Pharmaceutical Industry (ABPI) is the trade association for more than 70 companies in the UK producing prescription medicines. Its member companies research, develop, manufacture and supply more than 80 per cent of the medicines prescribed through the National Health Service (NHS).

The ABPI also represents companies engaged in the research and/or development of medicines for human use. In addition, its general affiliate membership is for all other organisations with an interest in the pharmaceutical industry.

The ABPI can be contacted at the following addresses:

12 Whitehall, London SW1A 2DY
Telephone: +44 (0) 870 890 4333
Fax: +44 (0) 20 7747 1414
Email: Please use our enquiry form
  

ABPI Scotland

Third Floor East, Crichton House, 4 Crichton’s Close, Canongate, Edinburgh, EH8 8DT
Telephone: +44 (0) 870 890 4333
Fax: +44 (0) 131 523 0491

The ABPI in Scotland has been established to work together with the Scottish Parliament, patients, healthcare professionals and managers of the NHS to ensure that the people of Scotland have access to the best quality healthcare, including modern medicines.

The pharmaceutical industry is one of the UK's most successful, providing top-quality employment, making high levels of balance of trade earnings, and developing world-beating modern medicines.  Scotland and the pharmaceutical industry together form a powerful combination, offering benefit for both the health and wealth of the nation.

ABPI Cymru Wales

2 Pentir Caspian, Stryd y Pierhead, Bay Caerdydd, CF10 4DQ
Ffon: 0870 890 4333
Facs: 0292 045 4298

Caspian Point 2, Pierhead Street, Cardiff Bay, CF10 4DQ
Telephone: 0870 890 4333
Fax: 0292 045 4298

ABPI Cymru Wales assists with the industry understanding of the evolving differences between Wales and the other home nations and contributes to Wales-only bodies, such as the All Wales Medicines Strategy Group and the NHS Industry Forum. The Staff at ABPI Cymru Wales participate in and monitor policy decisions that are likely to impact on the whole of the UK.

The ABPI Cymru Wales Industry Group (WIG) was formed in 2001 and is the voice and forum for the pharmaceutical industry in Wales. The ABPI Cymru Wales office supports the Group in this aim. Since its formation, WIG has been working in partnership with the National Assembly for Wales, NHS Wales and other key stakeholders, to help address the distinctive health needs of the people of Wales.

WIG currently has 32 member companies – having risen significantly in recent years to reflect the recognition within the industry of the growing importance and distinctiveness of the health agenda in Wales. Member companies include all the major global companies and smaller companies with a strong presence in Wales.

ABPI Northern Ireland

ABPI Northern Ireland
224 Lisburn Road
Belfast
BT9 6GE
Tel: 0870 890 4333
Fax: 029 2045 4298

ABPI Northern Ireland (ABPI NI) was set up in 2007 as the voice of the pharmaceutical industry in Northern Ireland - a regional presence for the Association of the British Pharmaceutical Industry, established in response to devolution and the changing political context.

ABPI NI represents the ABPI in addressing the distinctive health policy agenda in the region, where the specific health needs of the population are being tackled by a significant investment in health and social care by the Northern Ireland Executive.

The role of ABPI NI is to engender a greater understanding of the pharmaceutical industry in the region - to engage in dialogue with decision makers, health policy formers and healthcare providers. By enhancing communication and working effectively in partnership with stakeholders, we aim to improve the health and well-being of the people of Northern Ireland, and to encourage investment and employment opportunities.

ABPI NI is working to develop good relations with the Northern Ireland Executive and politicians from all parties in the Northern Ireland Assembly.

ABPI NI has already been recognised as a key stakeholder by the Department of Health, Social Services and Public Safety (DHSSPS) Pharmaceutical Clinical Effectiveness Group and is working to evolve a process perceived and recognised by all as being fit for purpose, consistent, transparent, robust and undertaken with appropriate rigour.